Pear Therapeutics initiates feasibility study to treat depressive symptoms in people with multiple sclerosis

This article was originally published here

Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018. Clinicians estimate that between 35-50% of people with MS

The post Pear Therapeutics initiates feasibility study to treat depressive symptoms in people with multiple sclerosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply